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Progressive renal failure is one of the main complications in
HbS/b-thalassemia (HbS/b-thal). Early identification of
patients at high risk of developing renal failure is of great
importance as it may allow specific measures to delay the
progression of renal damage and thus reduce the incidence
of end-stage renal failure and mortality. Early predictors of
renal impairment in HbS/b-thal remain to explore. Within this
context, we studied 87 compound HbS/b-thal patients
(36 males/51 females; median age 39 years) and 30 healthy
controls. In addition to conventional renal biochemistries
we measured serum cystatin-C (Cys-C), urine
N-acetyl-b-D-glucosaminidase (NAG) excretion and serum and
urinary b2-microglobulin (b2-M). Cystatin-C, NAG and serum
b2-M levels were higher in patients than controls. The
incidence of patients with high levels of Cys-C, NAG, and
b2-M was 32.1, 74.7, and 70.1% respectively, while only 6.8%
of patients had increased serum creatinine levels. Cystatin-C
and serum b2-M showed a strong correlation with creatinine
clearance and age, while NAG positively correlated with
proteinuria. An inverse correlation was also shown between
hemoglobin and b2-M, NAG, and Cys-C levels. Seven patients
with proteinuria received therapy with angiotensin-converting
enzyme (ACE) inhibitors. Changes of poteinuria positively
correlated with NAG levels. These results indicate that Cys-C is
an accurate marker of renal dysfunction, and urinary NAG
excretion can be considered as a reliable index of the tubular
toxicity, and possible predictor of proteinuria and eventual
renal impairment in HbS/b-thal patients. Furthermore, NAG
measurement may be used for monitoring ACE-inhibitors
therapy in HbS/b-thal patients with proteinuria.
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Renal damage is a frequent complication in sickle cell disease
(SCD) as a result of long-standing anemia and disturbed
circulation through the medullar capillaries.1 The underlying
mechanisms include chronic hypoxia, medullary ischemia,
and increased prostaglandin secretion that lead to glomerular
hypertrophy,2 increased glomerular permeability,3 and pro-
teinuria,4 which eventually result in chronic renal failure.
Furthermore, the hyperosmolar milieu of the medulla, a
condition favoring hemoglobin S (HbS) polymerization and
resulting in increased blood viscosity within the medullar
capillaries, leads to loss of concentrating capacity, urinary
acidification, and decreased potassium excretion.1–4 The
incidence of renal failure among SCD patients (both
homozygous HbS and HbS/beta-thalassemia (b-thal) pa-
tients) ranges from 5 to 18%.5–8 Platt et al.9 reported that
almost 9% of SCD patients who died due to disease
complications manifested overt renal failure, which was
identified as the major risk factor for early mortality in adult
patients with SCD.
Detection of the progressive renal damage using conven-
tional parameters, such as serum creatinine levels (Cr) or
creatinine clearance (Ccr) is often misleading. The early
development of glomerular hypertrophy enhances creatinine
excretion and gives false normal results of both Cr and Ccr.
Therefore, the renal dysfunction becomes evident rather late.
For that reason, the identification of markers that indicate
early renal dysfunction as well as further progression to end-
stage renal disease is highly desirable.
Cystatin-C (Cys-C) is a cysteine protease inhibitor, which
is produced by nearly all human cells and excreted into the
bloodstream. At a molecular weight of 13 kDa, the protein is
freely filtered by the renal glomerulus and then metabolized
by the proximal tubule. Therefore, its serum levels serve as an
endogenous parameter of glomerular filtration rate
(GFR).10,11 b2-Microglobulin (b2-M), a low molecular weight
protein, is freely filtered in the glomerulus wherefrom it is
totally reabsorbed and degraded in the renal tubules. Thus, it
is a sensitive marker of the glomerular filtration capacity of
the kidney. b2-M serum levels remain low in healthy
individuals as their urine contains almost no b2-M, while
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their elevation is associated with the presence of tubular
damage.12 N-Acetyl-b-D-glucosaminidase (NAG), a widely
distributed lysosomal enzyme found predominantly within
the renal proximal tubules, is also a sensitive indicator of
renal injury.13 The aim of this study was to evaluate whether
Cys-C, b2-M, and NAG excretion may serve as early
indicators of renal dysfunction in a large cohort of HbS/b-
thal patients. To our knowledge, such studies are not available
in the literature.
RESULTS
Basic characteristics of patients along with molecular b-thal
mutations, and markers of renal function are shown in
Table 1. Mild (300–1000 mg/24 h) and moderate
(1001–3000 mg/24 h) proteinuria was present in 25 (28.7%)
patients. All of them were asymptomatic, except one patient
who had both severe proteinuria (3650 mg/24 h) and elevated
Cr (282 mmol/l). Ccr ofo80 ml/min/1.73 m2 was found in 31
(35.6%) patients, while 13 (14.9%) patients had Ccr levels of
above 120 ml/min/1.73 m2. Abnormal serum Cr levels pre-
sented in only six patients (6.8%), while increased values of
Cys-C, NAG, and serum b2-M were observed in 28 (32.1%),
65 (74.7%), and 61 (70.1%) patients, respectively (Table 2).
Furthermore, HbS/b-thal patients had a dramatic increase of
Cys-C, NAG, and serum b2-M levels compared with controls,
while there was no difference between patients and controls
in terms of Cr (Table 1). All patients had some degree of
inability to maximally concentrate the urine.
Statistical analysis of the data revealed several correlations
which are summarized in Table 3. Age displayed a significant
correlation with serum b2-M, Cys-C, NAG, and proteinuria,
while it showed a negative correlation with Ccr. Hemoglobin
presented an inverse correlation with serum b2-M and Cys-C
and a significant association between hemoglobin and Ccr.
Ccr showed an inverse significant correlation with Cys-C,
when patients had a Ccr of below or equal to 90 ml/min
(Figure 1); Ccr had also an inverse correlation with serum b2-
M. Furthermore, Cys-C correlated with NAG, serum b2-M,
and Cr, while NAG correlated significantly with proteinuria.
Additionally, nine out of 26 patients who had proteinuria
(their values ranged from 800 to 4200 mg/24 h) were
subjected to renal biopsy. The pathology revealed focal
segmental glomerulosclerosis (FSGS) in five patients, glo-
merular hypertrophy with FSGS in two patients, and FSGS
with mesangial proliferative glomerulonephritis and deposits
of immunoglobulin A (IgA) and immunoglobulin M in the
glomerular capillary wall in one patient and FSGS with
Table 1 | Main characteristics of the patients (values are
expressed as mean7s.d.)
Parameters All patients N=87
Controls
N=30 P-value
Age (years) 42.6710.4 40.279.0 0.166
Sex 36M/51F 11M/19F 0.145
Interacting b0 39 (39),
b-Thalassemia genes (n) IVS1-1 (18),
FSC8 (2),
IVS1-110 (17),
IVS1-6 (11)
Hb (g/dl) 9.271.4 13.871.1 o0.0001
Serum creatinine (mmol/l) 69731 6178 0.083
Serum cystatin (mg/l) 1.070.6 0.870.1 0.003
Serum b2-microglobulin (mg/l) 2.872.4 0.970.1 o0.0001
Proteinuria (mg/24 h) 454.57686.0 57.4728.2 o0.0001
Creatinine clearance (ml/min/
1.73 m2)
92.6733.4 105.7712.2 0.002
NAG (U/day) 6.675.1 2.071.1 o0.0001
Spec. Gravity 1006.273.2 1015.072.7 o0.0001
Table 2 | Incidence of impaired renal function in 87
HbS/b-thal patients
Renal function parameter Patients (%)
Proteinuria
4300 (mg/24 h) 26 29.8
300–1000 (mg/24 h) 16 18.3
1001–3000 (mg/24 h) 9 10.3
43000 (mg/24 h) 1 1.1
Creatinine clearance
o80 ml/min/1.73 m2 31 35.6
Creatinine clearance
4120 ml/min/1.73 m2 13 14.9
Urine b2-M 40 mg/l 4 4.5
NAG 42 U/day 65 74.7
Serum creatinine 499 mmol/l 6 6.8
Cystatin-C 40.96 mg/l 28 32.1
Serum b2-M 41.8 mg/l 61 70.1
Table 3 | Significant correlations between markers of renal
function and various clinical parameters in patients with
Sickle cell/b-thalassemia
Parameter (1) Parameter (2) Spearman’s R P-level
Cys-C Age 0.45 o0.0001
Hb 0.209 0.05
Ccr 0.43 o0.0001
Serum Cr 0.52 o0.0001
Serum b2-M 0.875 o0.0001
NAG 0.315 0.002
NAG Age 0.228 o0.04
NS NS NS
Proteinuria 0.546 o0.00001
Serum b2-M Age 0.507 o0.0001
Hb 0.3 0.004
Ccr 0.38 o0.001
Serum Cr 0.39 o0.001
Ccr Age 0.27 0.009
Hb 0.269 0.012
Proteinuria Age 0.37 o0.001
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deposits of IgA in the last. Of the biopsied patients, the two
patients with apparent IgA nephropathy were removed from
analysis, as IgA nephropathy can case FSGS as well as
mesangial expansion and should not be included with SCD
nephropathy. All other seven patients received angiotensin-
converting enzyme (ACE) inhibitor (fosinopril, 10 mg daily
for 6 months) and they continue on treatment to date. Five
patients reduced the degree of proteinuria by 43.3–76.3%; the
other two patients showed an increase in urinary protein
excretion by 8.25–12.3% (Figure 2). Of interest is that the
above changes of urinary protein excretion correlated with
parallel changes of NAG (r¼ 0.691, Po0.001), that is, a clear
reduction of urinary NAG in patients who reduced their
proteinuria and a clear increase in patients who had not.
Conversely, Cys-C and b2-M levels did not show this
correlation.
DISCUSSION
The presence of nephropathy in SCD has been already
described since 1910, when Herrick described a young black
student with ‘anemia with peculiar elongated and sickle-
shaped red blood cells’, and a ‘slightly increased volume of
urine of low specific gravity’.14 Subsequently, additional
studies showed that the kidney in patients with SCD exhibits
numerous functional and structural abnormalities due to
hypoxia, acidosis, and hypertonicity that occur in the renal
medulla and promote HbS polymerization and red cell
sickling.15,16 Sickle cell nephropathy is a serious condition
and, once established, is no more reversible. In consequence,
physicians taking care of patients with this condition should
be able to detect the oncoming renal damage as early as
possible in order to institute measures which may delay its
progress. Routine findings of renal failure in all forms of SCD
(both homozygous HbS, and HbS/b-thal) include hyposthe-
nuria, proteinuria, increased serum creatinine and decreased
Ccr.7,17–19 The primary clinical tool for measuring renal
function, the serum Cr, is insensitive for the detection of
moderate alterations in renal function and is affected by
factors unrelated to renal activity, such as age, gender, race,
and lean muscle mass.20 Although measurement of Cr is
simple and easily available, almost 50% of patients with
impaired GFR have normal Cr,21 even though specific
enzymatic creatinine measurements are used.22 The goal of
the current study was to explore whether serum levels of Cys-
C and b2-M, and urinary excretion of NAG may serve as early
indicators of renal dysfunction in a large cohort of HbS/b-
thal patients.
Cys-C is a low molecular weight non-glycosylated cysteine
proteinase inhibitor, which participates in the intracellular
protein catabolism. Cys-C is freely filtered in the glomeruli
and totally reabsorbed in the proximal tubular cells where it
is catabolized; therefore, it is a perfect endogenous marker of
GFR.10 This observation has already been reported for
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Figure 1 | Correlation between creatinine clearance (Ccr) and
Cystatin-C (Cys-C). (a) Ccr showed an inverse significant correlation
with Cys-C, when patients had a Ccr of below or equal to 90 ml/min.
(b) On the contrary there was no correlation between Ccr and Cys-C
when patients had a Ccr of above 90 ml/min. Therefore, Cys-C
measurements are useful when glomerular filtration rate (GFR) is
altered only.
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Figure 2 | Changes of proteinuria and N-acetyl-b-D-glucosamini-
dase (NAG) in seven patients who received angiotensin-con-
verting enzyme (ACE) inhibitor, fosinopril 10 mg daily for 6
months. (a) Five patients reduced the degree of proteinuria by
43–76%; the other two patients showed an increase in urinary protein
excretion by 8–12%. (b) The same five patients had also a reduction of
NAG levels that ranged between 15 and 76%, while the two patients
who experienced an increase of proteinuria showed also an increase
in NAG values that ranged between 12 and 21%.
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various types of kidney disease.6,11 Our study confirmed this
result for HbS/b-thal patients as well. Abnormal levels of
serum Cys-C 32% of HbS/b-thal patients in contrast with
only 6.8% of them who had increased Cr values. Further-
more, increased Cys-C levels were strongly associated with
reduced Ccr values that were observed in 35% of HbS/b-thal
patients (Figure 1). Therefore, Cys-C seems to be a better
parameter than Cr to reveal renal impairment and is possibly
an earlier marker reflecting the oncoming renal failure in
HbS/b-thal, in comparison to Cr alone, as in other renal
diseases.10,11 Furthermore, Cys-C measurements confer
advantages (independence from height, gender, and muscle
mass) in the assessment of renal function in these patients
than conventional markers.
NAG is a widely distributed lysosomal enzyme contained
in the tubular epithelial cells and released in the urine as a
result of the tubulo-toxicity of proteinuria in the early stages
of idiopathic membranous nephropathy, glomerular hyper-
trophy, FSGS (glomerulosclerosis often progresses to renal
failure) and minimal changes disease.13 In the present study,
urinary NAG levels were increased in 74.7% of HbS/b-thal
patients. Since NAG has not been of plasmatic origin and has
not been filtered through the glomeruli, the enhanced NAG
urinary output is due to nonspecific release of tubular
proteins and not secondary to loss of glomerular selectivity.
Additionally, the quantity of daily protein excretion in the
urine displayed a significant correlation with the levels of
NAG. Urinary NAG excretion may therefore be considered as
a reliable marker of the tubular cell status in HbS/b-thal and
its assessment may be useful for the early recognition of the
malfunction of the proximal tubular epithelial cells in HbS/b-
thal patients.
Another low molecular weight protein, b2-M is freely
filtered in the kidney wherefrom it is reabsorbed and
degraded in the renal tubules. Impaired excretion of b2-M
due to glomerular damage causes an increase in serum
concentration; therefore, the levels of this microprotein may
serve as a sensitive marker of GFR, provided that inflamma-
tory, immunologic, and neoplastic disorders that also cause
increased b2-M levels in the serum are excluded.
23 Serum b2-
M values were higher than 1.8 mg/l in 70% of our patients,
and showed a strong correlation with Ccr. Thus, we may
suppose that b2-M may also serve as an endogenous marker
of GFR in HbS/b-thal. However, SCD has been well
recognized as a chronic inflammatory disease and we have
to keep in mind that serum b2-M may be influenced by this
condition.24,25
The above results supports that Cys-C is an early and
accurate marker of Ccr (GFR), while urinary NAG excretion
is a reliable and tubulo-toxicity marker of proteinuria.
Although, serum b2-M was correlated significantly with Ccr
its association with chronic inflammation may support that it
is not a specific index of Ccr in sickle cell nephropathy.
Moreover, these results are in keeping with Jovanovic et al.12
who reported that Cys-C and b2-M correlated significantly
with Ccr and age in patients with various renal diseases and
specified that Cys-C may be more sensitive than b2-M when
the glomerular injury is associated with significant protei-
nuria.
Our study also showed that Cys-C, NAG, and the b2-M
positively correlated with age in HbS/b-thal patients, as
observed in other studied groups with different renal
disorders.12
Hyposthenuria provides the first laboratory evidence of
defective medullary tonicity and is possibly of clinical
importance in HbS/b-thal patients, as it may cause dehydra-
tion, and increases the risk for the development of
vaso-occlussive crises. In our study, all patients had mild to
severe degree of inability to maximally concentrate their
urine, confirming the presence of renal impairment in
HbS/b-thal.
Proteinuria is detectable in 20–30% of patients with HbS/
HbS disease and in a lower incidence in patients with HbS/b-
thal.6,19,26,27 The underlying mechanisms include mesangial
phagocytosis of sickled cells and glomerular injury caused by
hyperfiltration and glomerular hypertrophy and, in rare cases
immune complex glomerulonephritis.28 In our study,
proteinuria (4300 mg/24 h) was detected in almost 30% of
patients. In the vast majority, proteinuria was mild or
moderate (o3 g/24 h), and increased with age, in accordance
with the respective literature.6,7,27
Five out of seven patients who received ACE inhibitors
reduced the degree of proteinuria; however, this favorable
effect was not confirmed in the other two patients. The
correlation between changes of proteinuria and NAG post-
ACE-inhibitors therapy supports the notion that urine
NAG excretion may serve as a useful marker for monitoring
the management of proteinuria with ACE-inhibitors
(Figure 2).
The histological findings of these seven HbS/b-thal
patients were not different than those observed in HbS/
HbS patients in the literature.6,28,29
In clinical practice to-day, the levels of Cr are widely
considered as a reliable rough estimate of GFR, although
various methodological flaws and differences in nutrition and
metabolism of creatinine are often interfering with its
measurements.23 More importantly, in SCD, the hyperfiltra-
tion of creatinine in the glomeruli may lead to normal
Cr values. In the present study, only 6.8% of HbS/b-thal
patients showed increased serum Crs, while the respective
incidence of abnormal Ccr in the whole cohort of patients
was 50%.
The severity of anemia had a negative effect on the renal
parameters Cys-C, serum b2-M and NAG in all patients
(Table 3). Within this context, considering that renal
impairment starts early in the course of SCD,5 we wonder
whether maintaining high hemoglobin levels by the admin-
istration of erythropoietin from early age may prevent the
development of renal failure. However, this remains to be
proven by other studies.
In conclusion, our results suggest that serum Cys-C, urine
NAG excretion and serum b2-M may be applied as early
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biochemical markers for the assessment of renal impairment
in HbS/b-thal patients. Serum Cys-C is a better parameter
than Cr in reflecting renal damage, mainly in patients
with low Ccr, while urine NAG excretion reflects better
proteinuria and its response to ACE-inhibitors therapy.
The early identification of patients at high risk of developing
renal failure is of great importance in HbS/b-thal, as it may
allow specific measures aiming to delay the progression of
renal damage and thus reduce the incidence of end-stage
renal failure and mortality; therefore, we suggest that Cys-C,
NAG, and serum b2-M measurements may help in this
aspect.
MATERIALS AND METHODS
Patients
We studied 87 patients with HbS/b-thal. Thirty-six patients were
men and 51 women; their median age was 39 years (range: 23–70
years). The patients had been diagnosed by demonstration of
positive sickling phenomenon and Hb electrophoresis at pH 8.6. b-
globin gene mutations were detected using standard methodology.
All patients were Caucasians, of Greek origin, had stable disease at
the time of evaluation, without sickle-cell crises or infections, and
had not been transfused for at least 3 months before. They were
regularly followed up at the Thalassemia Center of Laikon Hospital,
Athens, Greece. Informed consent was obtained from all patients
prior to inclusion in the study. The study was conducted with the
approval of the hospital ethical committee in keeping with the
guidelines of the Declaration of Helsinki.
Blood chemistry
Serum urea, creatinine, uric acid, sodium, potassium, calcium,
phosphates, magnesium, protein, and albumin were measured using
the Bayer-Advia 1650 Clinical Chemistry System (Tarrytown, NY,
USA). Serum Cys-C and b2-M were determined by particle enhance
immunonephelometry using the Dade-Behring BN Prospec nephelo-
meter (Dade Behring, Liederbach, Germany). Cystatin-C and b2-M
of healthy adults were considered as normal when their levels are
o0.96 and 1.8 mg/l respectively, according to manufacturer.
Urine chemistry
In 24 h urine samples measurements of creatinine, uric acid,
electrolytes, protein, and b2-M were assessed as previously described
for serum determinations. Urine NAG activity was measured
photometrically at 580 nm using a colorimetric assay (Roche
Diagnostics, Mannheim, Germany) and expressed as daily output
in U/day. NAG level in normal individuals has been referred by the
manufacturer as lower than 2 U/day. Ccr was calculated as the ratio
of urine creatinine (mmol/l) 24 h urine volume (l) over plasma Cr
(mmol/l). All Ccr results were adjusted for body surface area. Specific
gravity of the urine was measured automatically using the Arkray
urine autoanalyzer (Arkray Inc., Shiga, Japan). For the specific
gravity measurement, urine specimen of the first morning urination,
which remained at room temperature for not more than 1 h, was
used.
The measurement of the above parameters was performed in all
patients and in 30 healthy volunteers (controls), with similar age
and gender (observational study). Controls were Caucasians, of
Greek origin.
In addition to the above measurements, nine patients with
proteinuria had a renal biopsy.
Statistical analysis
Differences between patients and controls were evaluated using the
Mann–Whitney test. The Spearman’s rank correlation test was
employed to examine relationships between various parameters and
clinical patient characteristics. All P-values are two sided and
confidence intervals refer to 95% boundaries. Statistical analysis was
performed using the STATGRAFICS PLUS version 5.1 for Windows
program (Graphic Software System); plots were prepared using the
Sigma plot version 8.0 program (Jandel Co).
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